CV Therapeutics Ranexa review
Executive Summary
FDA's Cardiovascular & Renal Drugs Advisory Committee will review CV Therapeutics Ranexa (ranolazine) for treatment of chronic stable angina at its Dec. 9 meeting. Review of the partial fatty acid oxidation inhibitor was previously scheduled for mid-September but was cancelled because FDA and the company did not have enough time to prepare for the meeting. The meeting will take place at the Hilton in Gaithersburg, Md. beginning at 8 a.m. [To 1watch a webcast of the meeting, go to FDAAdvisoryCommittee.com]...
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.